Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis
Summary Background Non‐alcoholic steatohepatitis (NASH) is a form of progressive fatty liver disease that is strongly associated with insulin resistance, which suggests that insulin sensitizing agents such as metformin may be beneficial for NASH. Aim To assess the effects of metformin on insulin s...
Saved in:
| Published in | Alimentary pharmacology & therapeutics Vol. 29; no. 2; pp. 172 - 182 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.01.2009
Blackwell |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Summary
Background Non‐alcoholic steatohepatitis (NASH) is a form of progressive fatty liver disease that is strongly associated with insulin resistance, which suggests that insulin sensitizing agents such as metformin may be beneficial for NASH.
Aim To assess the effects of metformin on insulin sensitivity, body composition, serum alanine aminotransferase (ALT) levels and liver histology in patients with NASH.
Methods Patients underwent liver biopsy, metabolic profiling and imaging studies before and at the end 48 weeks of metformin (2000 mg/day) therapy. The primary endpoint was a three‐point improvement in the histological NASH activity index.
Results Of 28 patients enrolled, 26 (13 females; average age 44 years) completed 48 weeks of treatment and underwent repeat metabolic studies, imaging and liver biopsy. Thirty per cent achieved a histological response. Most patients lost weight, the average being 6 kg. There was a marked association between weight loss and improvements in NASH activity index and ALT levels (both, P < 0.01). Insulin sensitivity also improved, but the degree of change did not correlate with histological improvement.
Conclusion Metformin leads to improvements in liver histology and ALT levels in 30% of patients with NASH, probably by its effects in causing weight loss. |
|---|---|
| AbstractList | Background
Non‐alcoholic steatohepatitis (NASH) is a form of progressive fatty liver disease that is strongly associated with insulin resistance, which suggests that insulin sensitizing agents such as metformin may be beneficial for NASH.
Aim
To assess the effects of metformin on insulin sensitivity, body composition, serum alanine aminotransferase (ALT) levels and liver histology in patients with NASH.
Methods
Patients underwent liver biopsy, metabolic profiling and imaging studies before and at the end 48 weeks of metformin (2000 mg/day) therapy. The primary endpoint was a three‐point improvement in the histological NASH activity index.
Results
Of 28 patients enrolled, 26 (13 females; average age 44 years) completed 48 weeks of treatment and underwent repeat metabolic studies, imaging and liver biopsy. Thirty per cent achieved a histological response. Most patients lost weight, the average being 6 kg. There was a marked association between weight loss and improvements in NASH activity index and ALT levels (both,
P
< 0.01). Insulin sensitivity also improved, but the degree of change did not correlate with histological improvement.
Conclusion
Metformin leads to improvements in liver histology and ALT levels in 30% of patients with NASH, probably by its effects in causing weight loss. Summary Background Non‐alcoholic steatohepatitis (NASH) is a form of progressive fatty liver disease that is strongly associated with insulin resistance, which suggests that insulin sensitizing agents such as metformin may be beneficial for NASH. Aim To assess the effects of metformin on insulin sensitivity, body composition, serum alanine aminotransferase (ALT) levels and liver histology in patients with NASH. Methods Patients underwent liver biopsy, metabolic profiling and imaging studies before and at the end 48 weeks of metformin (2000 mg/day) therapy. The primary endpoint was a three‐point improvement in the histological NASH activity index. Results Of 28 patients enrolled, 26 (13 females; average age 44 years) completed 48 weeks of treatment and underwent repeat metabolic studies, imaging and liver biopsy. Thirty per cent achieved a histological response. Most patients lost weight, the average being 6 kg. There was a marked association between weight loss and improvements in NASH activity index and ALT levels (both, P < 0.01). Insulin sensitivity also improved, but the degree of change did not correlate with histological improvement. Conclusion Metformin leads to improvements in liver histology and ALT levels in 30% of patients with NASH, probably by its effects in causing weight loss. Non-alcoholic steatohepatitis (NASH) is a form of progressive fatty liver disease that is strongly associated with insulin resistance, which suggests that insulin sensitizing agents such as metformin may be beneficial for NASH. To assess the effects of metformin on insulin sensitivity, body composition, serum alanine aminotransferase (ALT) levels and liver histology in patients with NASH. Patients underwent liver biopsy, metabolic profiling and imaging studies before and at the end 48 weeks of metformin (2000 mg/day) therapy. The primary endpoint was a three-point improvement in the histological NASH activity index. Of 28 patients enrolled, 26 (13 females; average age 44 years) completed 48 weeks of treatment and underwent repeat metabolic studies, imaging and liver biopsy. Thirty per cent achieved a histological response. Most patients lost weight, the average being 6 kg. There was a marked association between weight loss and improvements in NASH activity index and ALT levels (both, P < 0.01). Insulin sensitivity also improved, but the degree of change did not correlate with histological improvement. Metformin leads to improvements in liver histology and ALT levels in 30% of patients with NASH, probably by its effects in causing weight loss. Non-alcoholic steatohepatitis (NASH) is a form of progressive fatty liver disease that is strongly associated with insulin resistance, which suggests that insulin sensitizing agents such as metformin may be beneficial for NASH.BACKGROUNDNon-alcoholic steatohepatitis (NASH) is a form of progressive fatty liver disease that is strongly associated with insulin resistance, which suggests that insulin sensitizing agents such as metformin may be beneficial for NASH.To assess the effects of metformin on insulin sensitivity, body composition, serum alanine aminotransferase (ALT) levels and liver histology in patients with NASH.AIMTo assess the effects of metformin on insulin sensitivity, body composition, serum alanine aminotransferase (ALT) levels and liver histology in patients with NASH.Patients underwent liver biopsy, metabolic profiling and imaging studies before and at the end 48 weeks of metformin (2000 mg/day) therapy. The primary endpoint was a three-point improvement in the histological NASH activity index.METHODSPatients underwent liver biopsy, metabolic profiling and imaging studies before and at the end 48 weeks of metformin (2000 mg/day) therapy. The primary endpoint was a three-point improvement in the histological NASH activity index.Of 28 patients enrolled, 26 (13 females; average age 44 years) completed 48 weeks of treatment and underwent repeat metabolic studies, imaging and liver biopsy. Thirty per cent achieved a histological response. Most patients lost weight, the average being 6 kg. There was a marked association between weight loss and improvements in NASH activity index and ALT levels (both, P < 0.01). Insulin sensitivity also improved, but the degree of change did not correlate with histological improvement.RESULTSOf 28 patients enrolled, 26 (13 females; average age 44 years) completed 48 weeks of treatment and underwent repeat metabolic studies, imaging and liver biopsy. Thirty per cent achieved a histological response. Most patients lost weight, the average being 6 kg. There was a marked association between weight loss and improvements in NASH activity index and ALT levels (both, P < 0.01). Insulin sensitivity also improved, but the degree of change did not correlate with histological improvement.Metformin leads to improvements in liver histology and ALT levels in 30% of patients with NASH, probably by its effects in causing weight loss.CONCLUSIONMetformin leads to improvements in liver histology and ALT levels in 30% of patients with NASH, probably by its effects in causing weight loss. |
| Author | LOOMBA, R. LIANG, T. J. MODI, A. SUMNER, A. E. NAGABHYRU, P. HOOFNAGLE, J. H. LUTCHMAN, G. KLEINER, D. E. BORG, B. B. RICKS, M. FELD, J. J. |
| AuthorAffiliation | Clinical Endocrinology Branch, NIDDK, National Institutes of Health (NIH), Bethesda, MD, USA Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD, USA Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA |
| AuthorAffiliation_xml | – name: Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA – name: Clinical Endocrinology Branch, NIDDK, National Institutes of Health (NIH), Bethesda, MD, USA – name: Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, MD, USA |
| Author_xml | – sequence: 1 givenname: R. surname: LOOMBA fullname: LOOMBA, R. – sequence: 2 givenname: G. surname: LUTCHMAN fullname: LUTCHMAN, G. – sequence: 3 givenname: D. E. surname: KLEINER fullname: KLEINER, D. E. – sequence: 4 givenname: M. surname: RICKS fullname: RICKS, M. – sequence: 5 givenname: J. J. surname: FELD fullname: FELD, J. J. – sequence: 6 givenname: B. B. surname: BORG fullname: BORG, B. B. – sequence: 7 givenname: A. surname: MODI fullname: MODI, A. – sequence: 8 givenname: P. surname: NAGABHYRU fullname: NAGABHYRU, P. – sequence: 9 givenname: A. E. surname: SUMNER fullname: SUMNER, A. E. – sequence: 10 givenname: T. J. surname: LIANG fullname: LIANG, T. J. – sequence: 11 givenname: J. H. surname: HOOFNAGLE fullname: HOOFNAGLE, J. H. |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20952620$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/18945255$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUU2P0zAQtdAitlv4CygXxCllYidujATSquJLWgkOyxFZk2RMXTlxid1le-Mn8Bv5JTi0dOG2voyl9-a9mXkX7GzwAzGWFbAo0nuxWRRCVjkHIRccoF6AqKVa3D5gsxNwxmbApcp5XYhzdhHCBgDkEvgjdl7Uqqx4Vc3Yl5Wzg23RZXG06F5mW-t8zELcdfvMm6ynaPzY2yFLJYtrSjzC2NMQJzjN9evHT3StX3tn29SXQL-mLUYbbXjMHhp0gZ4c65x9fvvmevU-v_r47sPq8ipvK6lUXpRYCgVoSDSFLMmgaBA7MiWqhkxNHUADskDFeaW6piuXVHYFgqlqbgwXc_b6oLvdNT11bZpuRKe3o-1x3GuPVv-PDHatv_obzZUCWS-TwPOjwOi_7ShE3dvQknM4kN8FvSxrpQRwkZhP_7U6efw9aSI8OxIwpLuaEYfWhhOPg6q4TAHNWX3gtaMPYSRzJwV6Sllv9BSmnsLUU8r6T8r69m7dU2trY7q4n5az7j4Crw4C362j_b2N9eWn6-knfgOa9sTB |
| CitedBy_id | crossref_primary_10_1097_MEG_0000000000001369 crossref_primary_10_3389_fendo_2020_00070 crossref_primary_10_3350_cmh_2025_0045 crossref_primary_10_3389_fphar_2020_584090 crossref_primary_10_1177_201010581001900106 crossref_primary_10_1111_apt_16794 crossref_primary_10_4155_cli_10_24 crossref_primary_10_1139_apnm_2015_0236 crossref_primary_10_1177_2042018817741852 crossref_primary_10_1111_hepr_12834 crossref_primary_10_2147_JIR_S413565 crossref_primary_10_1016_j_metabol_2022_155264 crossref_primary_10_1002_hep_29367 crossref_primary_10_1016_j_diabet_2012_11_002 crossref_primary_10_3390_medicina55050166 crossref_primary_10_1016_j_artere_2017_07_001 crossref_primary_10_1007_s40519_014_0139_y crossref_primary_10_1111_apt_15331 crossref_primary_10_1159_000539371 crossref_primary_10_1111_j_1463_1326_2011_01403_x crossref_primary_10_1007_s40265_018_1040_1 crossref_primary_10_1159_000541442 crossref_primary_10_1111_dom_13592 crossref_primary_10_1016_j_jceh_2019_06_003 crossref_primary_10_4093_jkd_2022_23_2_83 crossref_primary_10_1007_s00125_016_3952_1 crossref_primary_10_1038_s41401_022_00874_x crossref_primary_10_1080_13813455_2019_1680700 crossref_primary_10_1016_j_jdiacomp_2017_07_014 crossref_primary_10_1136_flgastro_2024_102856 crossref_primary_10_1111_j_1872_034X_2011_00780_x crossref_primary_10_1016_j_cld_2023_01_008 crossref_primary_10_3389_fendo_2022_1027484 crossref_primary_10_1016_j_cld_2017_08_012 crossref_primary_10_1158_1078_0432_CCR_15_2494 crossref_primary_10_1016_j_pharep_2018_10_013 crossref_primary_10_2337_dc18_0165 crossref_primary_10_14341_omet12714 crossref_primary_10_3389_fmicb_2023_1147067 crossref_primary_10_1042_BSR20181304 crossref_primary_10_1111_apt_12084 crossref_primary_10_1016_j_mce_2019_110539 crossref_primary_10_1210_en_2017_03231 crossref_primary_10_1002_hep_23716 crossref_primary_10_1093_humupd_dmu037 crossref_primary_10_3390_medicina59101789 crossref_primary_10_1007_s12325_013_0084_6 crossref_primary_10_1517_13543784_2013_833604 crossref_primary_10_1155_2015_254169 crossref_primary_10_1016_j_gtc_2011_06_001 crossref_primary_10_1172_jci_insight_128061 crossref_primary_10_4103_ejim_ejim_34_17 crossref_primary_10_1038_s41419_023_05623_4 crossref_primary_10_4254_wjh_v12_i9_533 crossref_primary_10_1016_j_ando_2023_05_002 crossref_primary_10_1016_j_jlr_2024_100564 crossref_primary_10_1210_clinem_dgae060 crossref_primary_10_1016_j_mayocp_2015_06_013 crossref_primary_10_1177_1756283X11403809 crossref_primary_10_1155_2012_716404 crossref_primary_10_3109_00365521_2012_719926 crossref_primary_10_1177_0884533611419668 crossref_primary_10_1007_s10620_010_1241_2 crossref_primary_10_1007_s13410_017_0577_y crossref_primary_10_1007_s10620_015_3907_2 crossref_primary_10_1186_1472_6882_14_253 crossref_primary_10_4254_wjh_v6_i4_199 crossref_primary_10_1053_j_gastro_2012_04_001 crossref_primary_10_1097_MED_0000000000000432 crossref_primary_10_1155_2012_464706 crossref_primary_10_1177_2042018811419157 crossref_primary_10_1080_19390211_2025_2465414 crossref_primary_10_1016_j_ejphar_2020_173461 crossref_primary_10_1016_j_ceca_2020_102336 crossref_primary_10_1016_j_mce_2015_02_018 crossref_primary_10_3390_ijms23137280 crossref_primary_10_33667_2078_5631_2019_2_20_395__30_36 crossref_primary_10_3390_diagnostics11040689 crossref_primary_10_1038_nrgastro_2013_193 crossref_primary_10_1016_j_cgh_2015_07_029 crossref_primary_10_1002_hep_24042 crossref_primary_10_1161_ATV_0000000000000153 crossref_primary_10_33590_emj_10314771 crossref_primary_10_1002_hep_27314 crossref_primary_10_1002_hep_26465 crossref_primary_10_22141_2224_0721_17_4_2021_237350 crossref_primary_10_3748_wjg_v26_i23_3249 crossref_primary_10_1016_j_bbrep_2021_101168 crossref_primary_10_1097_TP_0000000000002483 crossref_primary_10_1016_j_phrs_2020_104799 crossref_primary_10_1038_ajg_2012_128 crossref_primary_10_1097_MD_0000000000025817 crossref_primary_10_4254_wjh_v9_i16_715 crossref_primary_10_1007_s12325_009_0072_z crossref_primary_10_1111_j_1365_2036_2009_04230_x crossref_primary_10_14218_JCTH_2016_00061 crossref_primary_10_1155_2015_732870 crossref_primary_10_3748_wjg_v29_i37_5339 crossref_primary_10_1186_s12986_024_00871_3 crossref_primary_10_3892_ijmm_2015_2092 crossref_primary_10_1007_s40271_020_00485_w crossref_primary_10_1097_HEP_0000000000000323 crossref_primary_10_3350_cmh_2020_0100 crossref_primary_10_3892_br_2012_18 crossref_primary_10_1016_S0973_6883_12_60104_2 crossref_primary_10_1007_s11684_015_0384_0 crossref_primary_10_4291_wjgp_v7_i2_211 crossref_primary_10_1002_hep_23759 crossref_primary_10_1097_MEG_0000000000002754 crossref_primary_10_3390_jcm10081569 crossref_primary_10_52711_0974_360X_2023_00065 crossref_primary_10_3390_jcm11154294 crossref_primary_10_3390_ijms141122933 crossref_primary_10_1186_1878_5085_5_21 crossref_primary_10_1097_OGX_0000000000000312 crossref_primary_10_3390_metabo14040186 crossref_primary_10_3390_biom12121787 crossref_primary_10_3390_ph15040442 crossref_primary_10_1155_2020_3920196 crossref_primary_10_1016_j_cld_2015_10_009 crossref_primary_10_1038_ijo_2010_40 crossref_primary_10_3350_cmh_2023_0315 crossref_primary_10_1111_dom_13062 crossref_primary_10_1155_2017_8491742 crossref_primary_10_3390_foods10081719 crossref_primary_10_1016_j_plipres_2012_10_004 crossref_primary_10_1053_j_gastro_2016_03_008 crossref_primary_10_1053_j_gastro_2016_03_009 crossref_primary_10_1016_j_eprac_2022_03_010 crossref_primary_10_1097_MOG_0000000000000175 crossref_primary_10_3748_wjg_v23_i47_8263 crossref_primary_10_1177_1756283X09105462 crossref_primary_10_57105_2415_7252_2023_5_01 crossref_primary_10_3390_ijms19102863 crossref_primary_10_1016_j_metabol_2024_156080 crossref_primary_10_1016_j_ajpc_2024_100638 crossref_primary_10_2478_inmed_2022_0198 crossref_primary_10_1053_j_gastro_2016_03_004 crossref_primary_10_1172_JCI94505 crossref_primary_10_1007_s42000_018_0021_9 crossref_primary_10_1016_j_ecl_2016_06_005 crossref_primary_10_1016_j_jprot_2012_08_015 crossref_primary_10_1016_j_ejphar_2015_09_040 crossref_primary_10_1080_14656566_2018_1531126 crossref_primary_10_4093_dmj_2019_0034 crossref_primary_10_1111_j_1365_2036_2012_05121_x crossref_primary_10_1016_j_diabet_2015_11_001 crossref_primary_10_2337_db14_1947 crossref_primary_10_1016_j_phrs_2015_05_009 crossref_primary_10_1186_s12944_018_0762_0 crossref_primary_10_1016_j_arteri_2016_06_002 crossref_primary_10_1016_j_bbadis_2019_165621 crossref_primary_10_1097_MD_0000000000031437 crossref_primary_10_7570_jomes23054 crossref_primary_10_1016_j_ejphar_2024_176341 crossref_primary_10_1111_apt_15635 crossref_primary_10_3390_nu10111628 crossref_primary_10_12997_jla_2025_14_1_5 crossref_primary_10_1007_s40264_014_0147_x crossref_primary_10_1016_j_diabres_2014_01_003 crossref_primary_10_1292_jvms_18_0119 crossref_primary_10_4254_wjh_v7_i12_1652 crossref_primary_10_4093_jkd_2018_19_2_88 crossref_primary_10_3748_wjg_v23_i1_141 crossref_primary_10_1007_s00228_023_03586_1 crossref_primary_10_1016_j_gcb_2009_05_010 crossref_primary_10_1016_j_cld_2009_07_006 crossref_primary_10_3748_wjg_v20_i39_14219 crossref_primary_10_1111_jgh_13856 crossref_primary_10_1111_j_1365_2036_2008_03892_x crossref_primary_10_1002_dmrr_3386 crossref_primary_10_1007_s40265_012_0004_0 crossref_primary_10_1016_j_dld_2016_12_028 crossref_primary_10_1016_j_jhep_2016_04_021 crossref_primary_10_2174_1381612826666200122124116 crossref_primary_10_2217_17455057_5_2_191 crossref_primary_10_1016_j_diabet_2015_10_003 crossref_primary_10_1111_apt_12543 crossref_primary_10_1007_s00535_010_0291_8 crossref_primary_10_1053_j_gastro_2012_02_003 crossref_primary_10_1007_s10620_016_4062_0 crossref_primary_10_1007_s00261_014_0175_0 crossref_primary_10_1586_17474124_2014_894880 crossref_primary_10_1080_17512433_2021_1917374 crossref_primary_10_3390_ijms22147680 crossref_primary_10_1038_oby_2010_21 crossref_primary_10_1016_j_jhep_2024_04_031 crossref_primary_10_3803_EnM_2022_304 crossref_primary_10_5604_16652681_1171746 crossref_primary_10_1016_j_phrs_2020_104984 crossref_primary_10_1016_S1957_2557_17_30166_9 crossref_primary_10_1055_a_1997_0401 crossref_primary_10_3748_wjg_v20_i34_12082 crossref_primary_10_1186_s12944_017_0609_0 crossref_primary_10_1016_j_metabol_2016_04_004 crossref_primary_10_1016_j_tem_2013_05_004 crossref_primary_10_1016_j_cld_2013_09_005 crossref_primary_10_1186_s40842_016_0027_7 crossref_primary_10_3390_ijms22147571 crossref_primary_10_1111_dom_15700 crossref_primary_10_3390_jcm10245721 crossref_primary_10_3748_wjg_v23_i36_6549 crossref_primary_10_3389_fcvm_2022_1120085 crossref_primary_10_1146_annurev_physiol_021115_105331 crossref_primary_10_1016_j_curtheres_2019_100570 crossref_primary_10_1016_j_heliyon_2024_e41043 crossref_primary_10_12997_jla_2025_14_1_69 crossref_primary_10_1016_S1499_3872_13_60021_1 crossref_primary_10_1016_j_lfs_2022_120956 crossref_primary_10_1177_1535370215579161 crossref_primary_10_1186_s13098_019_0491_1 crossref_primary_10_1111_j_1365_2036_2008_03916_x crossref_primary_10_1002_mnfr_201900043 |
| Cites_doi | 10.1016/S1542-3565(04)00457-4 10.1210/jcem.85.8.6738 10.1016/S0016-5085(99)70506-8 10.1111/j.1572-0241.2005.41583.x 10.1038/nm1383 10.1038/79697 10.1007/BF00280883 10.1074/jbc.274.42.30028 10.1111/j.1365-2036.2005.02420.x 10.1053/j.gastro.2005.04.014 10.1002/hep.1840380427 10.1089/152091503322641060 10.1016/j.cgh.2008.07.013 10.1016/S0168-8278(98)80073-1 10.1111/j.1365-2036.2004.02025.x 10.1016/S0002-9440(10)62476-5 10.1056/NEJMoa060326 10.1016/S0025-6196(24)00530-5 10.1002/hep.20012 10.1053/jhep.2003.50193 10.1002/hep.20092 10.1056/NEJMoa012512 10.1016/j.cmet.2006.08.005 10.1111/j.1572-0241.2001.03553.x 10.1053/meta.2001.28078 |
| ContentType | Journal Article |
| Copyright | 2008 Blackwell Publishing Ltd. No claim to original US government works 2009 INIST-CNRS 2008 Blackwell Publishing Ltd 2008 |
| Copyright_xml | – notice: 2008 Blackwell Publishing Ltd. No claim to original US government works – notice: 2009 INIST-CNRS – notice: 2008 Blackwell Publishing Ltd 2008 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1111/j.1365-2036.2008.03869.x |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2036 |
| EndPage | 182 |
| ExternalDocumentID | PMC2990687 18945255 20952620 10_1111_j_1365_2036_2008_03869_x APT3869 |
| Genre | article Clinical Trial Journal Article Research Support, N.I.H., Intramural |
| GrantInformation_xml | – fundername: Intramural NIH HHS grantid: Z01 DK075013 |
| GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 24P 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFWVQ AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DC6 DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DTERQ E3Z EAD EAP EAS EBC EBD EBS EBX EJD EMB EMK EMOBN EST ESX EX3 F00 F01 F04 F5P FEDTE FIJ FUBAC FZ0 G-S G.N GODZA GX1 H.X HF~ HGLYW HVGLF HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TR2 TUS UB1 V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YOC ZZTAW ~IA ~WT AAYXX AGHNM AGQPQ AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c5699-14a4390afe3b164efa3baadef4a9bef8ed00b061a92259dbd47e4d1a0f582ff23 |
| IEDL.DBID | DR2 |
| ISSN | 0269-2813 1365-2036 |
| IngestDate | Thu Aug 21 18:21:40 EDT 2025 Fri Jul 11 12:14:49 EDT 2025 Fri May 30 10:59:22 EDT 2025 Mon Jul 21 09:16:42 EDT 2025 Tue Jul 01 00:27:39 EDT 2025 Thu Apr 24 23:02:58 EDT 2025 Wed Jan 22 16:57:21 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Human Hypoglycemic agent Biguanides Treatment Non alcoholic steatohepatitis Digestive diseases Hepatic disease Clinical trial Metformin |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5699-14a4390afe3b164efa3baadef4a9bef8ed00b061a92259dbd47e4d1a0f582ff23 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2036.2008.03869.x |
| PMID | 18945255 |
| PQID | 748993023 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2990687 proquest_miscellaneous_748993023 pubmed_primary_18945255 pascalfrancis_primary_20952620 crossref_primary_10_1111_j_1365_2036_2008_03869_x crossref_citationtrail_10_1111_j_1365_2036_2008_03869_x wiley_primary_10_1111_j_1365_2036_2008_03869_x_APT3869 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January 2009 |
| PublicationDateYYYYMMDD | 2009-01-01 |
| PublicationDate_xml | – month: 01 year: 2009 text: January 2009 |
| PublicationDecade | 2000 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
| PublicationTitle | Alimentary pharmacology & therapeutics |
| PublicationTitleAlternate | Aliment Pharmacol Ther |
| PublicationYear | 2009 |
| Publisher | Blackwell Publishing Ltd Blackwell |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Blackwell |
| References | 1998; 29 1985; 28 2004; 20 2001; 50 2000; 6 2006; 12 2005; 166 2005; 100 2004; 39 1980; 55 2000; 85 2005; 129 1999; 274 2003; 37 2002; 346 2003; 38 2005; 21 2003; 5 2006; 4 2008; 6 2004; 2 1999; 116 2001; 96 2006; 355 e_1_2_6_18_2 e_1_2_6_19_2 Ludwig J (e_1_2_6_2_2) 1980; 55 e_1_2_6_12_2 e_1_2_6_13_2 e_1_2_6_10_2 e_1_2_6_11_2 e_1_2_6_16_2 e_1_2_6_17_2 e_1_2_6_14_2 e_1_2_6_15_2 e_1_2_6_20_2 e_1_2_6_8_2 e_1_2_6_7_2 e_1_2_6_9_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_6_2 e_1_2_6_5_2 e_1_2_6_24_2 e_1_2_6_23_2 e_1_2_6_22_2 e_1_2_6_21_2 e_1_2_6_26_2 e_1_2_6_25_2 |
| References_xml | – volume: 6 start-page: 998 year: 2000 end-page: 1003 article-title: Metformin reverses fatty liver disease in obese, leptin‐deficient mice publication-title: Nat Med – volume: 4 start-page: 199 year: 2006 end-page: 210 article-title: Lipin 1 is an inducible amplifier of the hepatic PGC‐1 alpha/PPAR alpha regulatory pathway publication-title: Cell Metab – volume: 116 start-page: 1413 year: 1999 end-page: 9 article-title: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity publication-title: Gastroenterology – volume: 6 start-page: 1243 year: 2008 end-page: 8 article-title: Placebo in nonalcoholic steatohepatitis: insights into natural history and implications for future clinical trials publication-title: Clin Gastroenterol Hepatol – volume: 21 start-page: 871 year: 2005 end-page: 9 article-title: A phase 2 clinical trial of metformin as a treatment for non‐diabetic paediatric non‐alcoholic steatohepatitis publication-title: Aliment Pharmacol Ther – volume: 50 start-page: 1457 year: 2001 end-page: 61 article-title: Beneficial effects of metformin in normoglycemic morbidly obese adolescents publication-title: Metabolism – volume: 37 start-page: 1202 year: 2003 end-page: 19 article-title: Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference publication-title: Hepatology – volume: 5 start-page: 1003 year: 2003 end-page: 15 article-title: MINMOD Millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test publication-title: Diabetes Technol Ther – volume: 29 start-page: 495 year: 1998 end-page: 501 article-title: Non‐alcoholic steatohepatitis (NASH): a disease of emerging identity and importance publication-title: J Hepatol – volume: 28 start-page: 412 year: 1985 end-page: 9 article-title: Homeostasis model assessment: insulin resistance and beta‐cell function from fasting plasma glucose and insulin concentrations in man publication-title: Diabetologia – volume: 346 start-page: 393 year: 2002 end-page: 403 article-title: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin publication-title: N Engl J Med – volume: 12 start-page: 541 year: 2006 end-page: 8 article-title: CNTF reverses obesity‐induced insulin resistance by activating skeletal muscle AMPK publication-title: Nat Med – volume: 166 start-page: 1655 year: 2005 end-page: 69 article-title: The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology publication-title: Am J Pathol – volume: 85 start-page: 2767 year: 2000 end-page: 74 article-title: Effect of long‐term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome publication-title: J Clin Endocrinol Metab – volume: 20 start-page: 23 year: 2004 end-page: 8 article-title: Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial publication-title: Aliment Pharmacol Ther – volume: 96 start-page: 519 year: 2001 end-page: 25 article-title: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis publication-title: Am J Gastroenterol – volume: 39 start-page: 770 year: 2004 end-page: 8 article-title: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial publication-title: Hepatology – volume: 355 start-page: 2297 year: 2006 end-page: 307 article-title: A placebo‐controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis publication-title: N Engl J Med – volume: 38 start-page: 1008 year: 2003 end-page: 17 article-title: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐gamma ligand rosiglitazone publication-title: Hepatology – volume: 274 start-page: 30028 year: 1999 end-page: 32 article-title: Increased levels of nuclear SREBP‐1c associated with fatty livers in two mouse models of diabetes mellitus publication-title: J Biol Chem – volume: 55 start-page: 434 year: 1980 end-page: 8 article-title: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease publication-title: Mayo Clin Proc – volume: 100 start-page: 1082 year: 2005 end-page: 90 article-title: A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease publication-title: Am J Gastroenterol – volume: 129 start-page: 113 year: 2005 end-page: 21 article-title: The natural history of nonalcoholic fatty liver disease: a population‐based cohort study publication-title: Gastroenterology – volume: 2 start-page: 1107 year: 2004 end-page: 15 article-title: A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis publication-title: Clin Gastroenterol Hepatol – volume: 39 start-page: 188 year: 2004 end-page: 96 article-title: A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis publication-title: Hepatology – ident: e_1_2_6_13_2 doi: 10.1016/S1542-3565(04)00457-4 – ident: e_1_2_6_22_2 doi: 10.1210/jcem.85.8.6738 – ident: e_1_2_6_3_2 doi: 10.1016/S0016-5085(99)70506-8 – ident: e_1_2_6_16_2 doi: 10.1111/j.1572-0241.2005.41583.x – ident: e_1_2_6_24_2 doi: 10.1038/nm1383 – ident: e_1_2_6_15_2 doi: 10.1038/79697 – ident: e_1_2_6_19_2 doi: 10.1007/BF00280883 – ident: e_1_2_6_8_2 doi: 10.1074/jbc.274.42.30028 – ident: e_1_2_6_18_2 doi: 10.1111/j.1365-2036.2005.02420.x – ident: e_1_2_6_4_2 doi: 10.1053/j.gastro.2005.04.014 – ident: e_1_2_6_11_2 doi: 10.1002/hep.1840380427 – ident: e_1_2_6_20_2 doi: 10.1089/152091503322641060 – ident: e_1_2_6_26_2 doi: 10.1016/j.cgh.2008.07.013 – ident: e_1_2_6_6_2 doi: 10.1016/S0168-8278(98)80073-1 – ident: e_1_2_6_17_2 doi: 10.1111/j.1365-2036.2004.02025.x – ident: e_1_2_6_9_2 doi: 10.1016/S0002-9440(10)62476-5 – ident: e_1_2_6_14_2 doi: 10.1056/NEJMoa060326 – volume: 55 start-page: 434 year: 1980 ident: e_1_2_6_2_2 article-title: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease publication-title: Mayo Clin Proc doi: 10.1016/S0025-6196(24)00530-5 – ident: e_1_2_6_10_2 doi: 10.1002/hep.20012 – ident: e_1_2_6_5_2 doi: 10.1053/jhep.2003.50193 – ident: e_1_2_6_25_2 doi: 10.1002/hep.20092 – ident: e_1_2_6_21_2 doi: 10.1056/NEJMoa012512 – ident: e_1_2_6_7_2 doi: 10.1016/j.cmet.2006.08.005 – ident: e_1_2_6_12_2 doi: 10.1111/j.1572-0241.2001.03553.x – ident: e_1_2_6_23_2 doi: 10.1053/meta.2001.28078 |
| SSID | ssj0006702 |
| Score | 2.3959537 |
| Snippet | Summary
Background Non‐alcoholic steatohepatitis (NASH) is a form of progressive fatty liver disease that is strongly associated with insulin resistance,... Background Non‐alcoholic steatohepatitis (NASH) is a form of progressive fatty liver disease that is strongly associated with insulin resistance, which... Non-alcoholic steatohepatitis (NASH) is a form of progressive fatty liver disease that is strongly associated with insulin resistance, which suggests that... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 172 |
| SubjectTerms | Adult Biological and medical sciences Biopsy Digestive system Fatty Liver - drug therapy Female Gastroenterology. Liver. Pancreas. Abdomen Humans Hypoglycemic Agents - therapeutic use Liver - drug effects Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Metformin - therapeutic use Middle Aged Other diseases. Semiology Pharmacology. Drug treatments Pilot Projects Statistics as Topic Treatment Outcome |
| Title | Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2036.2008.03869.x https://www.ncbi.nlm.nih.gov/pubmed/18945255 https://www.proquest.com/docview/748993023 https://pubmed.ncbi.nlm.nih.gov/PMC2990687 |
| Volume | 29 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEB5KCqVQ-n64j0WHXr34IdlSb5u2SyiklJJALsVIlkRMNvbS9ULpqT-hv7G_pDO214nbHELpyQbt2Gg8I32Svv0G4DU3MrE4U4RcRBYXKLEJtSp5KJ2wsZDGRY72IQ8_ZgfH_MOJOBn4T_RfmF4fYtxwo8zoxmtKcG020yTvGFo4BA-UyFRmak54khoIH32-UJLK8o5-iCsOFSYyTqeknisfNJmp7qz1Bp3m-2oXV8HRv1mVl9FuN10t78HZrqM9S-Vsvm3NvPz-hwbk__HEfbg7oFq26MPwAdxw9UO4dTic2z-CL4P86Ip1VULesHW1alrWaduyxrNz1xJ4rmqGF4aYlI0EeGqum_rXj5-6r-ZblYwis21OHbHB22rzGI6X74_eHoRDYYewFJlSYcw14qBIe5caXK45r1OjtXWea2Wcl85GkUGgoRWONsoay3PHbawjL2TifZI-gT18s3sGLNGy5EZIW1rDEf0plQuTxy52hox9APnuIxbloHpOxTdWxaXVD3qvIO8NNTnJe8W3AOLRct0rf1zDZjaJk9EwQSRL0v8BsF3gFJjHdDija9dsNwWpACmq4BTA0z6OLt4qFZ0-C-zLJMLGH5BE-LSlrk47qXACG5nMA8i6ALp2R4rFpyO6e_6vhi_gdn_uRptVL2Gv_bp1rxC-tWYGNxf77_aXsy5BfwPZlzrY |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQkQCp4v0IheID16zysBObW4VaLdCtENpKvaDIjm01YklW3ayEeupP4DfyS5hxsmkDPVSI00bKzkaezNjf2LPfR8hbpkViYKUIGY8MFCixDpUsWSgsNzEX2kYW9yFnR9n0mH084Se9HBD-F6bjhxg23DAz_HyNCY4b0uMs9y1aMAf3PZGpyOQEAOVtFPj29dWXSy6pLPcNiFBzyDARcTpu67n2l0Zr1fZSrcBtrtO7uA6Q_t1XeRXv-gXr4AFZbIba9al8m6xbPSnP_2CB_E--eEju98CW7nWR-IjcsvVjcmfWH90_IV97BtIF9UIh7-iyWjQt9fS2tHH0u20RP1c1hQ8KsJQOPfB4u27qXxc_VSfoW5UUg7NtTi02hLfV6ik5Ptifv5-GvbZDWPJMyjBmCqBQpJxNNVRs1qlUK2WsY0pq64Q1UaQBaygJE4402rDcMhOryHGROJekz8gWPNm-IDRRomSaC1MazQAASplzncc2thqNXUDyzVssyp74HPU3FsWVAgi8V6D3ellO9F7xIyDxYLnsyD9uYLM7CpTBMAEwi-z_AaGbyCkglfF8RtW2Wa8KJAKSKOIUkOddIF0-VUg8gOYwllGIDV9AlvDxnbo69WzhiDcykQck8xF044EUe5_nePXyXw3fkLvT-eywOPxw9GmH3OuO4XDv6hXZas_W9jWguVbv-iz9DYVqPYE |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlhVAo6Tt1m6Y69OrFD8mWcgtNlvSREEoCuRQjWRIx2dpL1gulp_yE_sb-ks7IXiducwilJxvssdF4Rvokff6GkHdMi8TASBEyHhmYoMQ6VLJkobDcxFxoG1lchzw8yg5O2cczftbzn_BfmE4fYlhww8zw_TUm-Ny4cZJ7hhZ0wT0lMhWZnACevM-ySGCE7325lpLKcs8_hCmHDBMRp2NWz61PGg1VD-dqAV5zXbmL2_Do37TKm3DXj1fTR-Ri1dKOpnIxWbZ6Uv74QwTy_7jiMdnoYS3d7eLwCbln66dk_bDfuH9Gvvb6ozPqy4Ts0Hk1a1rqxW1p4-g32yJ6rmoKBwqglA4MeLxcN_Wvq5-qK-dblRRDs23OLdLB22rxnJxO90_eH4R9ZYew5JmUYcwUAKFIOZtqmK9Zp1KtlLGOKamtE9ZEkQakoSR0N9Jow3LLTKwix0XiXJK-IGvwZvuS0ESJkmkuTGk0A_gnZc51HtvYajR2AclXH7Eoe9lzrL4xK25Mf8B7BXqvL8qJ3iu-ByQeLOed9McdbLZHcTIYJgBlUfs_IHQVOAUkMu7OqNo2y0WBMkASSzgFZLOLo-u3ConbzxzaMoqw4QbUCB9fqatzrxWOaCMTeUAyH0B3bkixe3yCZ6_-1fAtWT_emxafPxx9ek0edHtwuHC1Rdbay6V9A1Cu1ds-R38Dtxg8OQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+trial+%3A+pilot+study+of+metformin+for+the+treatment+of+non-alcoholic+steatohepatitis&rft.jtitle=Alimentary+pharmacology+%26+therapeutics&rft.au=LOOMBA%2C+R&rft.au=LUTCHMAN%2C+G&rft.au=HOOFNAGLE%2C+J.+H&rft.au=KLEINER%2C+D.+E&rft.date=2009-01-01&rft.pub=Blackwell&rft.issn=0269-2813&rft.volume=29&rft.issue=2&rft.spage=172&rft.epage=182&rft_id=info:doi/10.1111%2Fj.1365-2036.2008.03869.x&rft.externalDBID=n%2Fa&rft.externalDocID=20952620 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-2813&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-2813&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-2813&client=summon |